Valuation: REGENXBIO Inc.

Market Cap 493M 434M 410M 372M 699M 47.34B 703M 4.91B 1.9B 24.15B 1.85B 1.81B 77.62B P/E 2026 *
-2.27x
P/E 2027 * -2.79x
Enterprise Value 484M 426M 403M 365M 686M 46.5B 690M 4.82B 1.86B 23.73B 1.82B 1.78B 76.25B EV / Sales 2026 *
2.89x
EV / Sales 2027 * 2.52x
Free-Float
93.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.95%
1 week-5.20%
Current month-21.37%
1 month-22.67%
3 months-28.72%
6 months-3.74%
Current year-48.12%
1 week 7.12
Extreme 7.12
8.14
1 month 7.12
Extreme 7.12
9.71
Current year 5.46
Extreme 5.455
16.19
1 year 5.46
Extreme 5.455
16.19
3 years 5.04
Extreme 5.035
28.8
5 years 5.04
Extreme 5.035
44.35
10 years 5.04
Extreme 5.035
85.1
Manager TitleAgeSince
Chief Executive Officer 64 2024-06-30
Director of Finance/CFO 45 2024-09-15
Chief Tech/Sci/R&D Officer 53 2025-02-28
Director TitleAgeSince
Chairman 78 2020-06-30
Chairman 51 2024-06-30
Director/Board Member 76 2015-10-14
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Tax

Chief Technology Officer

-234 0.0004%
9/1/26 Tax

Chief Financial Officer

-4,902 0.0074%
8/27/26 Buy

Director

53,407 0.0818%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-5.20%-22.59%-57.75% 488M
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-2.70%+37.74%+86.90% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
-0.14%-2.75%-14.13%+356.79% 25.73B
+0.57%+1.10%+1.02%-2.89% 24.75B
+1.10%+1.86%+25.07%-8.51% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%+2.01%+49.51%+160.70% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average -0.11%-0.91%+31.44%+143.22% 27.56B
Weighted average by Cap. -0.12%-1.06%+38.03%+125.75%

Financials

2026 *2027 *
Net sales 168M 148M 140M 127M 238M 16.11B 239M 1.67B 645M 8.22B 630M 616M 26.42B 217M 191M 180M 164M 307M 20.83B 309M 2.16B 835M 10.63B 815M 797M 34.16B
Net income -176M -155M -146M -133M -249M -16.9B -251M -1.75B -677M -8.62B -661M -647M -27.71B -200M -176M -167M -151M -284M -19.22B -285M -1.99B -770M -9.81B -752M -735M -31.52B
Net Debt -8.72M -7.67M -7.25M -6.58M -12.35M -837M -12.42M -86.82M -33.53M -427M -32.73M -32.02M -1.37B 53.61M 47.15M 44.59M 40.44M 75.95M 5.15B 76.39M 534M 206M 2.63B 201M 197M 8.44B
Logo REGENXBIO Inc.
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
Employees
371
Date Price Change Volume
26-09-28 US$7.470 +0.95% 1,325,833
26-09-25 US$7.400 +2.21% 1,276,586
26-09-24 US$7.240 -3.47% 1,516,274
26-09-23 US$7.500 -7.98% 1,113,282
26-09-22 US$8.150 +3.43% 1,202,480
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
7.470USD
Average target price
23.73USD
Spread / Average Target
+217.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RGNX Stock